Introduction

Advanced Medical Solutions Group plc (LSE:AMS) is a UK-based medical-technology company specialising in tissue-healing and surgical products, including wound closure, sealants and biosurgical devices. Best known for its LiquiBand tissue adhesives, Advanced Medical Solutions (AMS) has expanded its reach through Acquisition into surgical sutures and related products. A record year for sales, driven by both acquisitions and organic growth, has reaffirmed its position as a quality healthcare name on London’s growth market.

Why Advanced Medical Solutions (AMS) is in focus now

Advanced Medical Solutions (AMS) is in focus after reporting record full-year sales, with Revenue up sharply thanks to a combination of acquisition contributions and solid organic growth. The expansion into surgical sutures and clips, alongside continued growth in its flagship LiquiBand range and biosurgical devices, has broadened the Business and lifted profitability. A further Dividend increase has reinforced the company’s appeal to investors seeking exposure to defensive, growing medical-technology markets.

Business overview

Advanced Medical Solutions develops, manufactures and supplies products used in tissue healing and surgery. Its portfolio spans tissue adhesives and wound closure (notably the LiquiBand Brand), biosurgical devices such as sealants and haemostats, and, following acquisition, surgical sutures, clips and vascular temporary occlusion products. The company sells to healthcare providers and partners globally, combining its own branded products with original-equipment-manufacturer Supply relationships. Its markets are underpinned by structural Demand for surgical and wound-care solutions.

Latest Earnings explained

For the year ended 31 December 2025, Advanced Medical Solutions reported group revenue up about 29% to roughly £228.9m, from £177.5m, with the existing business delivering about 10% growth on a constant-currency basis and acquisitions adding the remainder. Adjusted EBITDA rose about 24% to roughly £49.9m, though the Margin edged lower to about 21.8% from 22.6%, reflecting mix and integration. Adjusted profit before tax rose about 15% to roughly £33.9m, while reported profit before tax increased about 81% to roughly £17.8m, helped by operational Leverage and acquisition contributions.

Revenue, profit, margins, Cash Flow and Balance Sheet

The 2025 figures show a business growing both organically and through acquisition. LiquiBand revenue grew about 10% to roughly £47.8m, biosurgical devices rose about 23% to roughly £27.8m, and the suture, clips and vascular temporary occlusion category surged about 64% to roughly £82.7m, reflecting the contribution of acquired surgical operations. The slight dip in adjusted EBITDA margin reflects the integration of lower-margin acquired activities, but the strong rise in reported profit before tax points to improving operational leverage. The company has historically maintained a healthy, cash-generative balance sheet supporting both acquisitions and dividends.

What management said

Management highlighted the record sales performance and the success of both organic growth and the expansion into surgical products. Commentary emphasised the strategic logic of broadening the portfolio into sutures and surgical devices, complementing the established LiquiBand and biosurgical ranges. The decision to raise the dividend reflected confidence in the company’s cash generation and prospects. The tone underlined AMS’s strategy of building a broader, higher-value surgical and tissue-healing business with international reach.

Latest news and announcements

Recent developments include the record full-year 2025 results, the strong growth in the surgical category reflecting acquisition contributions, the continued growth of LiquiBand and biosurgical devices, and the increased final dividend of 2.01p per share, taking the full-year dividend up about 10%. AMS has pursued acquisitions to broaden its surgical offering, and investors watch for further integration progress and any additional deals that fit its strategy.

Share-price performance and market reaction

Advanced Medical Solutions (AMS) shares have traded around 217p. The shares have responded to the record results and the progress of the company’s surgical expansion, though as a medical-technology business, sentiment can be affected by margin trends, integration of acquisitions, currency movements and healthcare-market conditions. The defensive, structurally growing nature of its markets has generally supported investor confidence, while the margin dip and integration are watch points.

Growth drivers

The main growth drivers for Advanced Medical Solutions (AMS) are continued growth of the LiquiBand tissue-adhesive range, expansion of the acquired surgical sutures and devices business, growth in biosurgical products, and international expansion. The integration of acquisitions offers scope for revenue and cost synergies, while the structural demand for surgical and wound-care products underpins the markets. Innovation and the broadening of the product portfolio support Long-term Growth, and a strong balance sheet enables further Investment.

Key risks for investors

Advanced Medical Solutions faces risks including the integration of acquisitions, which can pressure margins and carries execution risk, as the slight EBITDA-margin dip illustrates. The company is exposed to healthcare-market conditions, procurement and pricing pressures, and regulatory requirements for medical devices. Currency movements affect reported results given its international sales. Competition in wound care and surgical products is significant, and reliance on key products such as LiquiBand and on OEM relationships is a consideration. Reimbursement and healthcare-budget trends also influence demand.

Dividend position

Advanced Medical Solutions (AMS) is a progressive dividend payer, having raised its full-year 2025 dividend by about 10%, with an increased final dividend of 2.01p per share. Backed by cash generation, the dividend reflects management’s confidence and adds an income element to the investment case. While the Yield is modest, the combination of growth and a rising dividend is characteristic of a quality medical-technology compounder.

Outlook for the next 6–12 months

Over the next 6–12 months, the focus will be on continued organic growth, the integration and performance of the acquired surgical business, and margin progression as integration matures. Investors will watch for evidence that the broadened portfolio is delivering synergies and sustaining growth, alongside any further acquisitions. Healthcare-market conditions and currency movements will be external factors. The structural demand for the company’s products provides a supportive backdrop.

Investor takeaway

Advanced Medical Solutions (AMS) delivered record sales in 2025, combining organic growth in LiquiBand and biosurgicals with a substantial acquisition-led expansion into surgical products, and raised its dividend. The investment case rests on continued growth and successful integration, balanced against margin, integration, regulatory and currency risks. This article is for information only and is not financial advice; investors should do their own research.